KR20070058690A - 인다졸 화합물의 제조방법 - Google Patents

인다졸 화합물의 제조방법 Download PDF

Info

Publication number
KR20070058690A
KR20070058690A KR1020077009848A KR20077009848A KR20070058690A KR 20070058690 A KR20070058690 A KR 20070058690A KR 1020077009848 A KR1020077009848 A KR 1020077009848A KR 20077009848 A KR20077009848 A KR 20077009848A KR 20070058690 A KR20070058690 A KR 20070058690A
Authority
KR
South Korea
Prior art keywords
formula
compound
reaction
mixture
catalyst
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020077009848A
Other languages
English (en)
Korean (ko)
Inventor
브리짓 레이 에와니키
에릭 존 플라히브
애니 쥬디스 카스파리안
마크 브라이언 미첼
마이클 데이비드 페리
스테이시 앤 오닐-슬라베키
닐 윌라임 사흐
제임스 에드워드 사엔즈
빙 샤이
네보자 슬로보단 스탠코빅
제이야람 카츠리 스리랑암
킹핑 티안
슈 유
Original Assignee
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 화이자 인코포레이티드 filed Critical 화이자 인코포레이티드
Publication of KR20070058690A publication Critical patent/KR20070058690A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
KR1020077009848A 2004-11-02 2005-10-21 인다졸 화합물의 제조방법 Ceased KR20070058690A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US62463504P 2004-11-02 2004-11-02
US60/624,635 2004-11-02
US71707105P 2005-09-14 2005-09-14
US60/717,071 2005-09-14

Publications (1)

Publication Number Publication Date
KR20070058690A true KR20070058690A (ko) 2007-06-08

Family

ID=35744929

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077009848A Ceased KR20070058690A (ko) 2004-11-02 2005-10-21 인다졸 화합물의 제조방법

Country Status (14)

Country Link
US (1) US7232910B2 (enExample)
EP (1) EP1809621A1 (enExample)
JP (1) JP2008518900A (enExample)
KR (1) KR20070058690A (enExample)
AR (1) AR051754A1 (enExample)
AU (1) AU2005300310A1 (enExample)
BR (1) BRPI0518203A2 (enExample)
CA (1) CA2586174A1 (enExample)
IL (1) IL182693A0 (enExample)
MX (1) MX2007005291A (enExample)
NO (1) NO20071619L (enExample)
RU (1) RU2007116107A (enExample)
TW (1) TWI294421B (enExample)
WO (1) WO2006048744A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101679356A (zh) 2007-04-05 2010-03-24 辉瑞产品公司 适用于治疗哺乳动物异常细胞生长的6-[2-(甲基-氨甲酰基)苯基硫基]-3-e-[2-(吡啶-2-基)乙烯基]吲唑的晶型
WO2009055730A1 (en) 2007-10-25 2009-04-30 Genentech, Inc. Process for making thienopyrimidine compounds
EP2163544A1 (en) * 2008-09-16 2010-03-17 Pfizer, Inc. Methods of preparing indazole compounds
CA2949515C (en) 2009-01-08 2018-10-23 Axel Becker Polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof
TW201531309A (zh) 2011-09-30 2015-08-16 Pfizer N-甲基-2-〔3-((e)-2-吡啶-2-基-乙烯基)-1h-吲唑-6-基硫烷基〕苯甲醯胺之藥學組成物
JP2014533262A (ja) 2011-11-11 2014-12-11 ファイザー・インク 慢性骨髄性白血病を治療するためのn−メチル−2−[3−((e)−2−ピリジン−2−イル−ビニル)−1h−インダゾール−6−イルスルファニル]−ベンズアミド
US9899120B2 (en) 2012-11-02 2018-02-20 Nanotek Instruments, Inc. Graphene oxide-coated graphitic foil and processes for producing same
US10087073B2 (en) 2013-02-14 2018-10-02 Nanotek Instruments, Inc. Nano graphene platelet-reinforced composite heat sinks and process for producing same
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
WO2015067224A1 (en) 2013-11-08 2015-05-14 Zentiva, K.S. Salts of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethanyl] indazole
HUE046727T2 (hu) * 2013-12-06 2020-03-30 Vertex Pharma Az ATR-kináz inhibitoraként használható vegyület, 2-amino-6-fluoro-N-[5-fluoro-piridin-3-IL]-pirazolo-[1,5-A]-pirimidin-3-karboxamid, ennek elõállítása, különbözõ szilárd formái és ezek radioaktív nyomjelzett származékai
US10570202B2 (en) 2014-02-04 2020-02-25 Pfizer Inc. Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
RU2667486C2 (ru) * 2014-03-31 2018-09-20 Сэндзю Фармацевтикал Ко., Лтд. Производное алкинилиндазола и его применение
US10695426B2 (en) 2014-08-25 2020-06-30 Pfizer Inc. Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
WO2016108106A1 (en) * 2014-12-29 2016-07-07 Shilpa Medicare Limited An improved process for preparation of axitinib
KR20170132171A (ko) 2015-02-26 2017-12-01 메르크 파텐트 게엠베하 암 치료를 위한 pd­1 / pd­l1 저해제
US9580406B2 (en) 2015-04-28 2017-02-28 Signa S.A. De C.V. Processes for the preparation of axitinib
RU2766890C2 (ru) 2015-06-16 2022-03-16 Мерк Патент Гмбх Комбинированные способы лечения антагонистами pd-l1
BR112019006504A2 (pt) 2016-10-06 2019-06-25 Pfizer Inc. regime de dosagem de avelumabe para o tratamento de câncer
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
ES2982700T3 (es) 2019-04-18 2024-10-17 Synthon Bv Proceso para preparar axitinib, proceso para purificar el producto intermedio 2-((3-yodo-1H-indazol-6-il)tio)-n-metilbenzamida, proceso para purificar axitinib a través de la sal HCI de axitinib, forma sólida de la sal HCI de axitinib
IL315262A (en) 2022-03-03 2024-10-01 Pfizer Multiple specific antibodies related to IL-4, IL-13 and/or TSLP and their uses
WO2025157389A1 (en) 2024-01-22 2025-07-31 Iomx Therapeutics Ag Combinations of halogenated heterocyclic kinase inhibitors and vegfr inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) * 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
KR101099281B1 (ko) * 2003-03-03 2011-12-26 어레이 바이오파마 인크. p38 억제제 및 그의 사용 방법
KR20050119671A (ko) * 2003-04-03 2005-12-21 화이자 인코포레이티드 Ag013736을 포함하는 제형
US20080274192A1 (en) 2005-05-19 2008-11-06 Pfizer Inc. Pharmaceutical Compositions Comprising an Amorphous Form of a Vegf-R-Inhibitor

Also Published As

Publication number Publication date
WO2006048744A1 (en) 2006-05-11
BRPI0518203A2 (pt) 2009-03-10
TWI294421B (en) 2008-03-11
RU2007116107A (ru) 2008-11-10
EP1809621A1 (en) 2007-07-25
US7232910B2 (en) 2007-06-19
TW200621721A (en) 2006-07-01
AR051754A1 (es) 2007-02-07
IL182693A0 (en) 2007-09-20
US20060094881A1 (en) 2006-05-04
CA2586174A1 (en) 2006-05-11
MX2007005291A (es) 2007-07-19
NO20071619L (no) 2007-04-25
JP2008518900A (ja) 2008-06-05
AU2005300310A1 (en) 2006-05-11

Similar Documents

Publication Publication Date Title
US7232910B2 (en) Methods of preparing indazole compounds
US20070203196A1 (en) Methods of preparing indazole compounds
JP2008518901A (ja) インダゾール化合物を調製するための方法
CN111961034A (zh) 用作ret激酶抑制剂的化合物及其应用
CN101094836A (zh) 制备吲唑化合物的方法
CN112585126B (zh) 四环化合物的制备方法
CN107709298A (zh) 作为溴结构域抑制剂的螺[环丁烷‑1,3’‑二氢吲哚]‑2’‑酮衍生物
CN111183130A (zh) 苯并杂环衍生物及包含其的医药组合物
CN102140081A (zh) 制备抑制香草素亚型1(vr1)受体的吲唑基脲的方法
JP4820295B2 (ja) イソインドール誘導体の製造方法
TWI468405B (zh) 1H-吡唑并〔4,3-c〕異喹啉衍生物、其製備及其於醫療上之應用
WO2017167251A1 (zh) 1-(芳基甲基)喹唑啉-2,4(1h,3h)-二酮的制备工艺
KR20040034996A (ko) 리스페리돈의 개선된 제조방법
TWI884151B (zh) 製備4-苯基-5-烷氧基羰基-2-噻唑-2-基-1,4-二氫嘧啶-6-基]甲基]-3-側氧-5,6,8,8a-四氫-1H-咪唑并[1,5-a]吡-2-基]-羧酸之替代方法
JP5315337B2 (ja) トポテカン塩酸塩の結晶形およびその製造方法
BRPI0708560A2 (pt) processo para a preparação de um composto, e, composto
JP2025518047A (ja) TRPM3媒介性障害を治療するためのピラゾロ[1,5-a]ピリジン誘導体
KR20060085631A (ko) 아자바이사이클로[3.1.0]헥산 화합물의 제조방법
EP2163544A1 (en) Methods of preparing indazole compounds
JP2003531837A (ja) ナフトアミジン系ウロキナーゼ阻害薬
CN114621155A (zh) 一种制备卡马替尼的方法
KR101865868B1 (ko) 1-이소프로필-3-[5-[1-(3-메톡시프로필) 피페리딘-4-일]-[1,3,4]옥사디아졸-2-일]-1h-인다졸 옥살레이트의 대규모 제조공정
KR100758522B1 (ko) 신규 벤즈아미드 유도체 및 이의 제조법
JPH0316352B2 (enExample)
HK40103024A (en) Improved process for preparing aminopyrimidine derivatives

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20070430

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20081024

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20090106

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20081024

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I